HUVEC tube formation in Matrigel, suggesting that reduction of miR-125a has a proangiogenic effect. In conclusion, downregulation of miR-125a through local transfection with miR-125a inhibitor might be a new way to enhance endothelial cell proliferation and viability, thereby promoting the reendothelialization observed in response to intimal injury.
Introduction
The endothelial cells are of great physiological importance regulating transport between blood and the tissue cells, and furthermore, they provide an antithrombotic barrier protecting from subendothelial lipoprotein retention and inflammation [1] . Moreover, the endothelial cells release vasoactive substances such as nitric oxide and prostacyclin regulating vascular tone, blood flow and blood pressure [2] . Reendothelialization represents an important feature in vascular healing depending on migration and proliferation of endothelial cells [3] . Thus, stimulation of endothelial cell proliferation and viability is critical in order to promote endothelial healing and improve vascular function in response to loss of endothelial cells as a result of intimal injury.
MicroRNAs (miRs) are small, noncoding RNAs (21-25 nucleotides in length) which are supposed to regulate gene activity through mRNA destabilization and degradation and/or translational repression, mechanisms leading to attenuation of target protein expression [4] . Blockade of miR-92a expression reduces endothelial inflammation in mice, whereas miR-181b regulates endothelial cell NF-κB signaling, suggesting that these miRs are important for the endothelial dysfunction observed in vascular inflammation [5, 6] . Hergenreider et al. [7] reported that shear stress-stimulated human umbilical vein endothelial cells (HUVECs) show high expression of the miR-143/145 cluster and, moreover, that HUVECs control gene expression of cocultured vascular smooth muscle cells through extracellular vesicles enriched in miR-143/145. These studies suggest that miRs indeed are important for endothelial function. The miR-125 family is highly conserved and consists of three homologs, miR-125a, miR-125b-1 and miR-125b-2, which are believed to be associated with growth and proliferation [8] . Overexpression of miR-125a attenuates migration of SKBR3 breast cancer cells, suggesting that this miR plays a role in breast cancer carcinogenesis [9] . Ectopic expression of miR-125a attenuates proliferation of hepatocellular carcinoma through a mechanism involving repression of MMP11 and VEGF expression [10] . Taken together, these data suggest that overexpression of miR-125a inhibits cancer cell proliferation. Moreover, the miR-125 family seems to be strongly associated with neuronal development [11, 12] . The miR-125a is highly expressed in endothelial cells, but its functional importance in endothelial cell biology is unknown [13] .
In the present study, we assess the importance of miR125a for HUVEC proliferation and viability demonstrating that over-expression of miR-125a attenuates HUVEC proliferation and viability by inducing apoptosis, while downregulation of miR-125a expression has the opposite effect, i.e. it promotes HUVEC proliferation and reduces apoptosis. We conclude that inhibition of miR-125a represents a novel principle for stimulation of endothelial cell proliferation and viability that may offer a way to promote reendothelialization in association with stent-therapy where the endothelial cells are damaged.
Materials and Methods

Cells and Transfection
HUVECs and human arterial endothelial cells (HAECs) were purchased from Lonza and cultured in complete EGM-2 endothelial cell medium supplemented with all necessary growth factors and antibiotics as recommended by the manufacturer (Lonza). The mouse microvascular endothelial cell line bEnd.3 was purchased from ATCC and cultured in DMEM/Ham's F12 medium supplemented with antibiotics as recommended by ATCC. The cells were kept in a water-jacketed cell incubator at 5% CO 2 in air at 37 ° C. The cells were trypsinized (0.25% trypsin) upon reaching confluence and reseeded at a density of 50,000 cells/ml. Experiments were performed when cells reached 80% confluence at passages 2-7. miR-125a-5p mimic (miScript Syn-mmu-miR-125a-5p, Qiagen) and inhibitor (mirVana TM miRNA Inhibitor, Ambion) were transfected into HUVECs at a concentration of 20 n M using Oligofectamine transfection reagent (Life Technologies) according to the manufacturer's instructions. Transfection efficiency was similar from experiment to experiment and independent of passage number. Cell number, DNA synthesis, apoptosis, viability and endothelial cell tube formation were assessed at 96 h after the start of transfection. All experiments were performed in complete EGM-2 medium supplemented with growth factors, i.e. under growth-stimulated conditions.
Assessment of Cell Number, DNA Synthesis and Cell Viability
After washing in PBS, the cells were stained with trypan blue (Sigma Chemicals) and counted in a Bürker chamber as appropriate. DNA synthesis was determined by measuring incorporation of radio-labeled thymidine into newly synthesized DNA as previously described by Holm et al. [14] . Briefly, [ 3 H]-thymidine (1 μCi) was included during the last 2 h of the 96-hour transfection time period. At 96 h, the cells were washed in PBS, trypsinized, centrifuged and sonicated in 5 m M NaOH. After centrifugation and washing with 0.5 M trichloroacetic acid, the pellet was dissolved in Soluene. Liquid scintillation cocktail was added, and the radioactivity measured in a liquid scintillation counter (Beckman). Radioactivity was expressed as DPM and normalized to the total protein concentration in each sample. Protein was determined using a protein assay kit (Bio-Rad). Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described by Carmichael et al. [15] . Briefly, cells were seeded in 96 wells, transfected and incubated with 0.5 mg/ml MTT in fresh culture medium for 2 h at 37 ° C. After cell lysis in 100% DMSO, absorbance (540 nm) was determined using a Multiskan GO microplate spectrophotometer (Thermo Scientific).
Quantitative Real-Time RT-PCR
Total RNA, including miRs, was extracted and purified using miRNeasy kit (Qiagen). Concentration and quality of RNA was assessed using a NanoDrop 2000C spectrophotometer (Thermo Scientific). Template RNA was reverse transcribed to cDNA using miScript II RT kit (Qiagen). The relative expression of miRs was analyzed by quantitative real-time RT-PCR using miScipt SYBR Green PCR kit (Qiagen) and miScript Primer Assays (Mm_miR-125a_1, Hs_RNU6-2_1, Qiagen) on a StepOnePlus real-time thermal cycler from Applied Biosystems. Each sample was analyzed in duplicate and miR-125a expression analyzed using the delta CT method described by Pfaffl [16] . SNORD61 and U6 snRNA was included as house-keeping reference RNA. Identical results were observed when miR-125a expression was normalized to SNORD61 and U6. Therefore, only data normalized to U6 are included in the data presentation.
Western Blotting
After washing in PBS, the cells were lysed in SDS sample buffer (Tris-HCl 62.5 m M , pH 6.8, 2% SDS, 10% glycerol, 1 m M phenylmethylsulfonyl fluoride). The samples were sonicated for 2 × 10 s, boiled and centrifuged. Supernatants were collected and total protein determined by a Bio-Rad protein determination kit to assure equal loading in each lane. The proteins were separated by SDS-PAGE using Criterion TGX any kD precast gels (Bio-Rad). The same amount of protein was loaded in each lane. After separation, the proteins were transferred to nitrocellulose membrane by electroblotting overnight at 4 ° C. The membrane was blocked in 1% casein (w/v) in TBS (Bio-Rad) and then incubated overnight with rabbit polyclonal Bcl2, Mcl-1, MUC1 or caspase 3 antibodies (Gene Tex) at a dilution of 1: 1,000 or a mouse monoclonal heat shock protein 90 (Hsp90) antibody (Chemicon International) at a dilution of 1: 10,000. The membranes were washed three times in TBS-T, and the immunoreactive bands were visualized by chemiluminescence using HRP-conjugated secondary anti-rabbit or anti-mouse antibodies followed by SuperSignal West Femto chemiluminescence reagent (Thermo Scientific). The immunospecific bands were analyzed by photodensitometric scanning and normalized to Hsp90 serving as internal control [17] . Images were acquired using a LI-COR Odyssey Fc instrument (LI-COR Biosciences).
Annexin V Flow Cytometry
In order to assess apoptosis, cells were washed with PBS and incubated with FITC-labeled annexin V and the fluorescence viability dye 7-aminoactinomycin D (7-AAD) using the FITC annexin V apoptosis kit (BD). The proportion of annexin V-positive and 7-AAD-negative cells was determined by flow cytometry using an Accuri C6 flow cytometer (BD). Cells in early stages of apoptosis are annexin V positive and 7-AAD negative. Gates for annexin Vand 7-AAD-positive cells were set using fluorescence minus one control. 20,000 events were recorded in each sample.
Assessment of HUVEC Tube Formation in Matrigel
After transfection, HUVECs were seeded in Matrigel (Matrigel TM Phenol red-free) from BD in RPMI-1640 medium (Gibco) supplemented with 2 m M L -glutamine, 2% FCS and antibiotics at a density of 40,000 cells per well in a 24-well plate. Formation of tube-like structures was assessed in photographs obtained by a Nikon TMS phase-contrast microscope equipped with a digital camera (Pixelink, Nikon).
Statistics
Values are presented as means ± SEM. Statistical significance was calculated using ANOVA and Student's two-tailed t test for unpaired comparisons with Bonferroni correction for post hoc analysis as appropriate. p values <0.05 were considered statistically significant.
Results
MiR-125a Regulates HUVEC DNA Synthesis
The endogenous expression of miR-125a transcript was similar in HUVECs and in HAECs, suggesting that miR-125a show similar expression in primary human endothelial cells from different segments of the vascular tree ( fig. 1 ) . Moreover, miR-125a expression in the mouse brain microvascular endothelial cell line bEnd.3 cells was similar to that observed in HUVECs and HAECs ( fig. 1 ) . Transfection of HUVECs with miR-125a mimic increased their level of miR-125a by about 9,000 times at 96 h compared to controls transfected with a noncoding construct, showing successful transfection with the miR-125a mimic ( fig. 2 a) . The miR-125a mimic attenuated HUVEC DNA synthesis by 98% compared to controls ( fig. 2 b) . Transfection with miR-125a inhibitor downregulated miR-125a expression by about 90% compared to controls ( fig. 2 c) , and, interestingly, transfection with miR-125a inhibitor upregulated HUVEC DNA synthesis 6-fold compared to controls ( fig. 2 d) .
MiR-125a Controls HUVEC Apoptosis
Transfection with miR-125a mimic for 96 h caused a dramatic reduction in HUVEC cell number compared to control cells transfected with the noncoding construct ( fig. 3 a, b) , while, interestingly, transfection with the miR125a inhibitor increased cell number ( fig. 3 a, b) . We determined the proportion of annexin V-positive HUVECs by flow cytometry after transfection with either miR-125a mimic or miR-125a inhibitor in order to assess the involvement of miR-125a in endothelial cell apoptosis. The miR-125a mimic increased the proportion of apoptotic cells 2-3 times compared to control cells ( fig. 3 c) . Interestingly, the miR-125a inhibitor reduced the proportion of apoptotic cells by about 40% compared to control ( fig. 3 c) . Cell viability, assessed by the MTT assay at 96 h, was increased by 85% in HUVECs transfected with the miR-125a inhibitor and reduced by 70% in HUVECs treated with the miR-125a mimic ( fig. 4 ) , confirming that endothelial cell viability is regulated by miR-125a through apoptosis.
Overexpression of miR-125a Attenuates Bcl2 and Upregulates Caspase 3 Protein Expression in HUVECs
Transfection with miR-125a mimic for 96 h attenuated expression of the antiapoptotic protein Bcl2 in HUVECs by about 30% compared to control cells transfected with noncoding construct ( fig. 5 a) . Transfection with miR-125a inhibitor had no effect on Bcl2 protein expression (97 ± 11% in cells transfected with miR-125a inhibitor vs. 100 ± 15% in control cells, n = 3 in each group, data normalized to the housekeeping protein Hsp90). Neither Mcl-1, another antiapoptotic member of the Bcl2 family, nor the well-known antiapoptotic protein MUC1 [8] was affected by the miR-125a mimic (data not shown). The miR-125a mimic increased cas- pase 3 protein expression by about 2 times compared to control cells ( fig. 5 b) . These data suggest that miR-125a-induced endothelial cell apoptosis involves upregulation of caspase 3 and downregulation of the antiapoptotic Bcl2 protein.
Inhibition of miR-125a Promotes HUVEC Tube Formation
Assessment of HUVEC tube formation in Matrigel showed that transfection with the miR-125a inhibitor for 96 h stimulated tube formation compared to control cells ( fig. 6 ). In fact, at 24 h after implantation in Matrigel, tubes were only observed in cells transfected with miR125a inhibitor and not in control cells ( fig. 6 ). Transfection with miR-125a mimic had a strong negative impact on cell survival resulting in less than 10% viable cells remaining after transfection with miR-125a mimic. Therefore, it was impossible to perform the Matrigel assay on miR-125a mimic-transfected cells.
Discussion
In the present study, we show that miR-125a controls human endothelial cell proliferation and viability through a mechanism involving regulation of apoptosis. Transfection of HUVECs with miR-125a mimic promotes apoptosis and reduces cell number, while, on the other hand, transfection with miR-125a inhibitor reduces apoptosis and instead promotes endothelial cell DNA synthesis and increases cell number. Moreover, we show that inhibition of miR-125a expression increases HUVEC tube formation in Matrigel, providing functional evidence that miR125a inhibition stimulates reendothelialization in vitro. Lack of endothelial healing and endothelial cell coverage represents a serious problem in stent therapy. Here, we suggest that inhibition of endothelial cell miR-125a expression may be used to stimulate reendothelialization in conditions such as stent therapy where the endothelial cells are damaged.
Previous studies show that miR-125a plays an important role in carcinogenesis and cancer cell proliferation [10, 18] . MiR-125a regulates cancer cell proliferation through apoptosis, but also other mechanisms such as regulation of oncogene expression are involved in the control of cancer cell proliferation by miR-125a. Infection of human breast cancer SKBR3 cells with retroviral constructs stimulating miR-125a expression reduces cell growth and migration and, furthermore, suppresses cellular expression of the oncogenes ERBB2 and ERBB3, suggesting that miR-125a-induced downregulation of breast cancer cell proliferation involves reduced ERBB2 and ERBB3 oncogene expression [9] . In the present study, we demonstrate that miR-125a regulates also human endothelial cell proliferation and viability. Importantly, we show that miR-125a control endothelial cell viability through a mechanism involving apoptosis.
The endothelial cell proapoptotic effect induced by overexpression of miR-125a is demonstrated by different readouts such as reduced cell number and DNA synthesis, attenuated cell viability demonstrated by the MTT assay, elevated proportion of annexin V positive cells and upregulated caspase 3 expression. On the other hand, attenuation of miR-125a expression by transfection with miR-125a inhibitor causes an antiapoptotic effect demonstrated by increased cell number and DNA synthesis, increased cell viability and reduced proportion of annexin V-positive cells. We show that the antiapoptotic protein Bcl2 is reduced by miR-125a, suggesting that miR-125a-induced apoptosis of HUVECs involves reduced Bcl2 expression. Members of the Bcl2 family have been reported to represent direct miR-125 targets in different cellular systems such as intestinal epithelial IEC-6 cells [8, 19] . Thus, our data showing that Bcl2 is a miR-125a target in HUVEC endothelial cells confirm previous reports in other experimental models. Interestingly, miR-125b negatively regulates Bcl2 through direct binding to the 3 ′ -UTR of the human Bcl2 gene, suggesting that also miR-125a acts through this mechanism [20] . However, we cannot completely ex- clude that also other miR-125a targets are involved in miR-125a-regulated endothelial cell proliferation and apoptosis. VEGF-A is an important proangiogenic factor previously reported to be regulated by miR-125a [10, 21] . The HUVEC cell culture medium (complete EGM-2 medium from Lonza) contains optimal concentrations of human VEGF (0.2-10 μg/ml), and, thus, it is highly unlikely that the miR-125a inhibitor-induced proangiogenic effect is due to an upregulation of HUVEC VEGF-A production.
In conclusion, we show that downregulation of miR125a expression promotes human endothelial cell proliferation and elevates their viability and proangiogenic properties through an antiapoptotic mechanism. Inhibition of endothelial cell miR-125a expression may represent a way to promote endothelial cell healing in conditions, such as stent therapy, where the endothelium is damaged. Future studies in animal models addressing the use of local transfection with miR-125a inhibitor to promote reendothelialization following vascular injury will be important.
